The Society for Immunotherapy of Cancer (SITC) hosted Session 106b during the 38th Annual Meeting & Pre-Conference Programs on Friday, November 3, 2023. Available here are the presentation slides and video from “Session 106b: Microbiome and Cancer” as permitted by presenters.
Melody Smith, MD, MS – Stanford University School of Medicine
Jennifer Wargo, MD, MMSc – The University of Texas MD Anderson Cancer Center
Cancer immunotherapy has led to new advances in the treatment of cancer patients. Immune checkpoint blockade targeting CTLA-4 and/or PD-(L)1 has improved outcomes in patients with late-stage cancer. Patients with hematological malignancies have also benefited from cellular therapies, particularly with CAR T cells. In patients who receive these treatments, there is an increasing understanding of what causes therapeutic resistance or relapse. The goal of this session is to explore how the intestinal microbiome impacts efficacy and toxicity after these therapies. The intestinal microbiome will also be assessed in terms of its regulatory mechanisms in the context of cancer immunotherapy.
To view the entire program schedule (including presenter permission to post) please click here.
SITC 2023 Annual Meeting: Friday, November 301:38:25